# Pinetree Therapeutics

> Pinetree Therapeutics is a Cambridge, Massachusetts biotech founded in 2019 that develops antibody-based targeted protein degraders for cancer. Its AbReptor and TAER-TAB platforms use modular bispecific and multispecific antibodies to hijack the body's own lysosomal machinery and eliminate disease-driving membrane-bound and extracellular proteins - including drug-resistant receptor tyrosine kinases that conventional inhibitors cannot reach. Led by founder and CEO Ho-Juhn Song, Ph.D., the preclinical company has raised roughly $111M to date, struck a $500M+ EGFR-degrader option deal with AstraZeneca, and is advancing lead oncology programs toward Phase I.

- **Founded:** 2019
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Ho-Juhn Song (Founder & CEO)
- **Team size:** ~37 employees
- **Products:** AbReptor, TAER-TAB (Tumor Associated Essential Receptor Targeting AntiBody), EGFR degrader program, Degrading antibody-drug conjugates (dADC)
- **Notable:** Raised an oversubscribed $47M Series B in October 2025 amid a difficult biotech funding climate, Secured a $500M+ potential-value EGFR-degrader option deal with AstraZeneca in July 2024, Built two proprietary antibody-based degradation platforms, AbReptor and TAER-TAB

## Products & services

- **AbReptor** — A modular, best-in-class antibody platform that creates bispecific and multispecific protein degraders. It co-engages a target receptor and the cell's endocytic machinery to drive internalization and lysosomal degradation of membrane-bound and extracellular proteins, including drug-resistant receptor tyrosine kinases refractory to existing TKIs and checkpoint therapies.
- **TAER-TAB (Tumor Associated Essential Receptor Targeting AntiBody)** — An antibody-based receptor degradation platform that targets and degrades drug-resistant or difficult-to-treat receptors found across many tumor types and on immune and disease cells.
- **EGFR degrader program** — Lead preclinical oncology candidate degrading EGFR; exclusively optioned globally by AstraZeneca in July 2024. Advancing toward Phase I.
- **Degrading antibody-drug conjugates (dADC)** — A next-generation concept combining AbReptor degradation with antibody-drug conjugate payload delivery, in early development.

## Achievements

- Raised an oversubscribed $47M Series B in October 2025 amid a difficult biotech funding climate
- Secured a $500M+ potential-value EGFR-degrader option deal with AstraZeneca in July 2024
- Built two proprietary antibody-based degradation platforms, AbReptor and TAER-TAB
- Raised roughly $111M in total funding since founding in 2019
- Demonstrated preclinical efficacy degrading drug-resistant receptor tyrosine kinases refractory to existing therapies

## Latest updates

- **2025-10** — Closed an oversubscribed $47M Series B to advance lead preclinical oncology programs toward Phase I and expand the AbReptor platform.
- **2024-07** — Closed $17M Series A and entered a global EGFR-degrader option collaboration with AstraZeneca worth over $500M in potential milestones.
- **2022-06** — Secured $23.5M Series A1 to develop its platform technology for unmet medical needs.

## Links

- Website: https://pinetreetx.com
- LinkedIn: http://www.linkedin.com/company/pinetree-therapeutics

---

Profile page: https://yespress.io/pinetree-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18